Transnetyx Acquires Laragen

Quintara Biosciences Acquires Laragen Sanger Sequencing Business from Transnetyx

September 15, 2025

Biotechnology

Quintara Biosciences has completed the acquisition of the Laragen Sanger Sequencing business (formerly operated by Transnetyx), effective September 15, 2025. The purchase preserves local operations and customer service in Los Angeles while expanding Quintara’s California sequencing footprint and capabilities.

Solvias Acquires Cergentis

July 13, 2022

Biotechnology

Swiss analytical contract research and manufacturing company Solvias acquired Utrecht-based genomics services provider Cergentis on July 12, 2022. The deal adds Cergentis' proprietary Targeted Locus Amplification (TLA) genomic analysis capabilities to Solvias' biologics and cell & gene therapy testing platform to expand its advanced-therapy testing services globally.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Transnetyx Acquires a-tune

March 22, 2022

Software

Transnetyx, a Memphis-based provider of outsourced genetic services, has acquired a-tune, a Germany-based developer of vivarium data management and compliance software. The deal will combine Transnetyx's laboratory services with a-tune's software to streamline animal research facility operations, simplify data management, and enhance compliance for research organizations worldwide.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.